2 results
Approved WMOCompleted
1. To assess the effect of odanacatib 50 mg once weekly versus placebo on lumbar spine BMD over 24 months.2. To assess the safety and tolerability of odanacatib 50 mg once weekly compared to placebo.
Approved WMOPending
Primary Objectives:• To assess the pharmacokinetics (PK) of bempedoic acid (ETC-1002 and ESP15228) in pediatric patients (6 to 17 years of age) with heterozygous familial hypercholesterolemia (HeFH) treated for 8 weeks.Secondary Objectives:• To…